EUVIMEDEUVIMED entdecken
Crossref

Differential Biliary Adverse Event Signals Among Glp-1 Receptor Agonists: A FAERS Disproportionality Analysis

Alvina, Huda Jaffar, Chidera N Onwuzo, Abdelkader Chaar, Mohamed Eisa

Digestive Diseases and Sciences · 2026

DOI: 10.1007/s10620-026-10017-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive Diseases and Sciences, 2026. Verfasst von Alvina und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY, USA. alvina.1898@gmail.com. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Adverse Drug Reaction Reporting Systems, Hypoglycemic Agents, Biliary Tract Diseases. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Biliary adverse events (AEs) have been reported with glucagon-like peptide-1 receptor agonists (GLP-1RAs), but within-class differences remain unclear. METHODS: We conducted a disproportionality analysis of FAERS comparing biliary outcomes (cholelithiasis, cholecystitis, biliary colic, bile duct stone, and cholangitis) across semaglutide, tirzepatide, liraglutide, exenatide, and dulaglutide; semaglutide was used as the reference agent. Proportional reporting ratios (PRR), reporting odds ratios (ROR), 95% confidence intervals, and Fisher exact tests were calculated. Subgroup analyses and sensitivity analyses were performed. RESULTS: After deduplication, 3460 reports were analyzed: semaglutide 1797, tirzepatide 1363, liraglutide 1033, exenatide 999, and dulaglutide 574. Compared with semaglutide, exenatide and tirzepatide showed lower reporting for bile duct stone (PRR 0.39 and 0.58), while exenatide and dulaglutide showed lower reporting for biliary colic (PRR 0.30 and 0.50). Dulaglutide showed higher reporting for cholangitis (PRR 1.65). Exenatide, liraglutide, and tirzepatide showed higher reporting for cholecystitis (PRR 1.12, 1.07, and 1.05) and cholelithiasis (PRR 1.33, 1.21, and 1.15). Subgroup findings were consistent with heterogeneity mainly observed for bile duct stone and biliary colic. Sensitivity analyses was largely concordant, although rarer outcomes lost significance. CONCLUSIONS: Biliary AE reporting varies across GLP-1RAs, highlighting agent-specific differences within class and the need for individualized prescribing and counseling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsAdverse Drug Reaction Reporting SystemsHypoglycemic AgentsBiliary Tract DiseasesHumansTirzepatideSemaglutideExenatideGlucagon-Like PeptidesRecombinant Fusion ProteinsImmunoglobulin Fc FragmentsLiraglutide

Stichwörter der Autor:innen

Biliary adverse eventsDisproportionality analysisFDA adverse event reporting systemGlucagon-like peptide-1 receptor agonists

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsTirzepatideSemaglutideExenatideGlucagon-Like PeptidesRecombinant Fusion ProteinsImmunoglobulin Fc FragmentsLiraglutidedulaglutideHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY, USA. alvina.1898@gmail.com.
  • Department of Internal Medicine, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY, USA.
  • Division of Gastroenterology and Hepatology, SUNY Upstate Medical University, Syracuse, NY, USA.

Zitieren

APA

Alvina, Jaffar, H., Onwuzo, C. N., Chaar, A., & Eisa, M. (2026). Differential Biliary Adverse Event Signals Among Glp-1 Receptor Agonists: A FAERS Disproportionality Analysis. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-026-10017-5

Vancouver

Alvina, Jaffar H, Onwuzo CN, Chaar A, Eisa M. Differential Biliary Adverse Event Signals Among Glp-1 Receptor Agonists: A FAERS Disproportionality Analysis. Digestive Diseases and Sciences. 2026. doi:10.1007/s10620-026-10017-5

BibTeX
@article{Alvina2026,
  author = {Alvina and Jaffar, Huda and Onwuzo, Chidera N and Chaar, Abdelkader and Eisa, Mohamed},
  title = {Differential Biliary Adverse Event Signals Among Glp-1 Receptor Agonists: A FAERS Disproportionality Analysis},
  journal = {Digestive Diseases and Sciences},
  year = {2026},
  doi = {10.1007/s10620-026-10017-5}
}
Kostenlos starten →